Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership
07 Enero 2025 - 3:53PM
Edgar (US Regulatory)
JOINT FILING AGREEMENT
This Joint Filing Agreement, dated as of January 7, 2025, is by and among Reprogrammed Interchange LLC and Reid Hoffman (the foregoing are collectively referred to herein as the “Filers”).
Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G and/or 13D with respect to Common Stock, par value $0.0001 per share of Vor Biopharma, Inc. beneficially owned by them from time to time.
Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13G and/or 13D (and any amendments thereto) on behalf of each of such parties, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.
This Joint Filing Agreement may be terminated by any of the Filers upon one week’s prior written notice or such lesser period of notice as the Filers may mutually agree.
Executed and delivered as of the date first above written.
REPROGRAMMED INTERCHANGE LLC
By: /s/ Frank Huang
Name: Frank Huang
Title: Manager
REID HOFFMAN
/s/ Reid Hoffman
Reid Hoffman
Vor Biopharma (NASDAQ:VOR)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
Vor Biopharma (NASDAQ:VOR)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025